Covid-19 antidote VINCOV-19 ready for Phase-3 trials, market

The University of Hyderabad (UoH) and the Centre for Cellular Molecular Biology (CCMB) in collaboration with VINS Bioproducts Limited, a leading immunological company based in Hyderabad, announced the successful completion of the Phase-two clinical trials of VINCOV-19, India's first antidote and a cure against SARS-CoV-2 virus.

Related Keywords

Hyderabad , Andhra Pradesh , India , Telangana , Vinayk Nandicoori , Aatmanirbhar Bharat , Krishnanh Harshan , Nooruddin Khan , Centre For Cellular Molecular Biology , School Of Life Sciences , University Of Hyderabad Uo , University Of Hyderabad , Reuters , Department Of Animal Biology , Cellular Molecular Biology , Associate Professor , Animal Biology , Life Sciences , Siddharth Daga , Chief Executive Officer , Sars Cov 2 Virus , Pandemic , Corona , Covid 19 , Covid 19 Pandemic , Vaccination , Vincov 19 , Vins Bioproducts Limited , Immunological Company , Clinical Trials , Omicron Variant , Mutations , Covid Mutations , Vaccinology ,